An anti-ICOSL antibody (AMG557) has been evaluated in patients affected by SjS (NCT02334306) or by active SLE (NCT04058028) but has revealed no statistically significant efficacy in treated patients compared to placebo group, suggesting that inhibition of the ICOS pathway alone may be insufficient to impact disease. Here, ICOSLG is linked to systemic lupus erythematosus.